Pharmaceutical composition for preventing or treating sarcopenia, comprising Anti-aging factor in nigrostriatal dopaminergic neural system as active ingredient
A pharmaceutical composition targeting the substantia nigra-striatal dopaminergic nervous system addresses sarcopenia by inducing anti-aging, improving muscle function, and reducing metabolic disease risk through enhanced mitochondrial function and dopamine neuron preservation.
Patent Information
- Application Number
- PCT/KR2026/095651
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-07
- Filing Date
- 2026-04-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for sarcopenia, a muscle disease characterized by muscle mass and function decline due to aging or diabetes, are inadequate and do not effectively address the underlying muscle degeneration, leading to increased prevalence of metabolic diseases and impaired physical function.
A pharmaceutical composition containing an anti-aging factor within the substantia nigra-striatal dopaminergic nervous system, potentially administered as a gene therapy, to induce anti-aging and improve muscle function.
The composition effectively prevents and treats sarcopenia by enhancing mitochondrial function, preserving dopamine neurons, and improving motor function and lean body mass, thereby reducing the risk of metabolic diseases and enhancing daily life activities.
Smart Images

Figure KR2026095651_12112026_PF_FP_ABST
Abstract
Description
Pharmaceutical composition for the prevention or treatment of sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopaminergic nervous system as an active ingredient
[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient, and preferably, said composition may include the induction of anti-aging within substantia nigra dopamine neurons as an active function.
[0002] Muscles are a major component of the body that, along with bones, maintain the body's overall shape, and muscles and bones are collectively called the musculoskeletal system. Muscles are composed of bundles of muscle fibers, which are muscle cells, and they play a role in generating power while simultaneously protecting body organs such as bones, joints, and internal organs.
[0003] Muscle breakdown and degeneration increase due to factors such as aging and diabetes, and if this phenomenon persists, muscle diseases may develop. Sarcopenia, one such muscle disease, is characterized by a decrease in muscle mass and function due to aging or diabetes, and is caused by factors such as reduced protein intake and lack of exercise. Additionally, cachexia, a form of sarcopenia caused by cancer, is the most common symptom among cancer patients and manifests due to muscle inflammation resulting from the cancer itself or the toxicity of anticancer drugs.
[0004] Sarcopenia causes a direct decrease in muscle strength, leading to reduced metabolism and increased body fat due to the decline and impairment of various physical capabilities. This, in turn, contributes to a higher prevalence of metabolic diseases such as hypertension, diabetes, arthritis, obesity, and cancer. Furthermore, sarcopenia is a condition that negatively impacts daily life because the resulting loss of muscle strength makes it difficult to walk and impairs independent physical function. Consequently, there is an urgent need for the development of fundamental treatments for sarcopenia beyond exercise and nutrition.
[0005] The objective of the present invention is to provide a novel therapeutic approach based on central nervous system regulation that can prevent and treat sarcopenia caused by normal aging.
[0006] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopaminergic nervous system as an active ingredient.
[0007] In addition, the present invention provides a health functional food composition for preventing or improving sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient.
[0008] In addition, the present invention provides a feed composition for preventing or improving sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient.
[0009] In addition, the present invention provides a method for treating sarcopenia comprising the step of administering a composition containing an anti-aging factor as an active ingredient to an individual.
[0010] The present invention can be usefully utilized to improve the universal quality of life based on the maintenance of skeletal muscle function in an aging society by effectively preventing and improving age-related sarcopenia through the induction of anti-aging of the central nervous system, particularly the substantia nigra-striatal dopaminergic nervous system.
[0011] Figure 1 shows a decrease in dopamine neurons in the substantia nigra of the midbrain of aged mice (20 months old) compared to young mice (3 months old), along with a decrease in the expression of SIRT3, an anti-aging factor, within the dopamine neurons.
[0012] Figure 2 shows the confirmation of GFP expression in dopamine neurons 4 weeks after injecting AAV-SIRT3-GFP and the control AAV-GFP into mouse midbrain substantia nigra dopamine neurons, respectively.
[0013] Figure 3 shows the confirmation of increased expression of mitochondrial respiratory chain, ATP synthesis, and dopamine signaling pathway genes 4 weeks after the introduction of AAV-SIRT3 into mouse midbrain substantia nigra dopamine neurons.
[0014] Figure 4 shows that SIRT3 expression increases in aged mice with AAV-SIRT3 introduced into dopaminergic neurons of the mouse midbrain substantia nigra, and p16 INK4a The expression of shows a decreasing trend, confirming the preservation of mitochondrial-associated protein expression.
[0015] Figure 5 shows the preservation of dopamine neurons and the quantitative preservation of dopamine metabolites in aged mice with AAV-SIRT3 introduced into dopamine neurons in the substantia nigra of the mouse midbrain.
[0016] Figure 6 shows the reduction in apoptosis and necrosis protein expression in aged mice in which AAV-SIRT3 was introduced into mouse midbrain substantia nigra dopamine neurons.
[0017] Figure 7 shows the improvement in age-related motor function and preservation of lean body mass in aged mice with AAV-SIRT3 introduced into dopaminergic neurons of the mouse midbrain substantia nigra.
[0018] Figure 8 shows p16 in the muscle region of aged mice introduced with AAV-SIRT3 within mouse midbrain substantia nigra dopaminergic neurons. INK4a It indicates a decrease in expression and confirmation of the preservation of Synaptophysin protein expression.
[0019] Figure 9 shows the confirmation of gene expression and protein expression levels of the SIRT family (SIRT1~7) 4 weeks after injection of AAV-SIRT3 into mouse midbrain substantia nigra dopamine neurons.
[0020] The present invention will be described in more detail below.
[0021]
[0022] The present invention provides a pharmaceutical composition for the prevention or treatment of sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopaminergic nervous system as an active ingredient.
[0023] Preferably, the composition may include anti-aging induction within substantia nigra dopamine neurons as an effective function.
[0024] Preferably, the anti-aging factor can regulate the anti-aging of the substantia nigra-striatal dopaminergic neural system of the midbrain.
[0025] Preferably, the composition may be a gene therapy drug.
[0026] Preferably, the gene therapy agent can be introduced into the substantia nigra of the midbrain.
[0027] Preferably, the anti-aging factor may be one or more SIRT families selected from the group consisting of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.
[0028] Preferably, the composition may have the effect of improving age-related exercise function and preserving lean body mass.
[0029] Preferably, it is possible to prevent or treat diseases selected from the group consisting of muscular atrophy, muscular dystrophy, sarcopenia, myopathy, myasthenia, muscular injury, and cachexia, as well as the sarcopenia mentioned above.
[0030] Preferably, the sarcopenia may be obese sarcopenia or age-related sarcopenia.
[0031]
[0032] In this specification, the “substantia nigra-striatal dopamine neural system” is a neural circuit in which nerve cells distributed in the substantia nigra of the brain transmit the neurotransmitter dopamine to the striatal region.
[0033] In this specification, the “pharmaceutical composition” may be prepared in a unit dose form or contained in a multi-dose container by formulation using a pharmaceutically acceptable carrier according to a method that can be easily carried out by a person skilled in the art to which the invention pertains.
[0034] The above-mentioned pharmaceutically acceptable carriers are those commonly used in formulations and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.
[0035] In the present invention, the content of the additive included in the pharmaceutical composition is not particularly limited and can be appropriately adjusted within the content range used in conventional formulations.
[0036] The above pharmaceutical composition may be provided in one or more formulations selected from the group consisting of gels, emulsions, injectables, and aerosols according to conventional methods, but is not limited thereto.
[0037] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable carriers and diluents for formulation. The pharmaceutically acceptable carriers and diluents include, but are not limited to, excipients such as starch, sugar, and mannitol; fillers and extenders such as calcium phosphate; cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose; binders such as gelatin, alginates, and polyvinylpyrrolidone; lubricants such as talc, calcium stearate, hydrogenated castor oil, and polyethylene glycol; disintegrants such as povidone and crospovidone; and surfactants such as polysorbate, cetyl alcohol, and glycerol.
[0038] The above-mentioned pharmaceutically acceptable carriers and diluents may be biologically and physiologically compatible with the subject. Specifically, the carriers and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, polyvinylpyrrolidone, and water. In addition, non-aqueous solvents may include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, ethyl oleates, and synthetic oils.
[0039] The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., within the substantia nigra of the midbrain, within the spinal canal, intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method. For oral administration, it may be formulated into tablets, troches, lozenges, water-soluble suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups, or elixirs. For parenteral administration, it may be formulated into injectable solutions, suppositories, powders for respiratory inhalation, aerosols for sprays, ointments, powders for topical application, oils, creams, etc.
[0040] The dosage of the pharmaceutical composition of the present invention may vary depending on the subject's condition and body weight, age, gender, health status, dietary constitutional specificity, properties of the formulation, degree of disease, time of administration of the composition, method of administration, duration or interval of administration, excretion rate, and form of the drug, and may be appropriately selected by a person skilled in the art. For example, it may be in the range of about 0.1 to 10,000 mg / kg, but is not limited thereto, and may be administered once or several times a day.
[0041] In the present invention, the 'object' may be a mammal including a human, but is not limited to these examples.
[0042]
[0043] In addition, the present invention provides a health functional food composition for preventing or improving sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient.
[0044] In this specification, the term “health functional food” refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body, and is a food with high medical or medical effects that is processed to efficiently exhibit biological regulatory functions in addition to nutritional supply; it may be used interchangeably with terms known in the art, such as “functional food.”
[0045] In the health functional food composition according to the present invention, the health functional food may be manufactured into a powder, granule, tablet, capsule, syrup, or beverage, and there are no limitations on the form in which the health functional food may take, and it may include all foods in the conventional sense. For example, beverages and various drinks, fruits and processed foods thereof (canned fruit, jam, etc.), fish, meat and processed foods thereof (ham, bacon, etc.), breads and noodles, cookies and snacks, dairy products (butter, cheese, etc.), etc. are possible, and it may include all functional foods in the conventional sense. In addition, it may also include foods used as animal feed.
[0046] The above-mentioned health functional food composition may be prepared by further including food-grade acceptable food additives and appropriate other auxiliary ingredients commonly used in the industry. For example, it may additionally contain flavoring agents, natural carbohydrates, sweeteners, vitamins, electrolytes, coloring agents, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents, etc. In particular, the above-mentioned natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol; and as sweeteners, natural sweeteners such as taumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.
[0047] The effective dose contained in the health functional food according to the present invention can be appropriately adjusted according to the purpose of use.
[0048]
[0049] In addition, the present invention provides a feed composition for preventing or improving sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient.
[0050] In the present invention, the term "feed" refers to a substance that supplies organic or inorganic nutrients necessary for maintaining the life and rearing of an individual. The feed may include nutrients such as energy, protein, lipids, vitamins, and minerals required by the individual consuming the feed, but is not specifically limited thereto. The individual refers to the subject of rearing and includes any living organism capable of consuming the feed of the present invention without limitation.
[0051] The feed composition of the present invention can be produced in various forms such as dry feed, semi-moist feed, and wet feed according to methods known in the art, and can be made in any one of the following forms, for example, powder, granules, pills, pellets, jelly, canned feed, biscuits, croquettes, nuggets, flakes, snacks, etc., but is not limited thereto.
[0052] The feed composition of the present invention may include one or more carriers, excipients, or diluents, and examples of said carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Additionally, it may further include fillers, anticoagulants, lubricants, wetting agents, flavorings, emulsifiers, and preservatives.
[0053] In addition, the feed composition of the present invention may include components commonly added to feed, such as carbohydrates, proteins, fats, minerals, vitamins, minerals, and water. There are no particular limitations on the types of each of these components, and any commonly used in the field may be used.
[0054]
[0055] In addition, the present invention provides a method for treating sarcopenia comprising the step of administering a composition containing an anti-aging factor as an active ingredient to an individual.
[0056] Preferably, the composition may be a gene therapy drug.
[0057] Preferably, the gene therapy agent can be introduced into the substantia nigra of the midbrain.
[0058]
[0059] Hereinafter, the present invention will be described in detail with reference to examples to aid in understanding. However, the following examples are merely illustrative of the content of the present invention and the scope of the present invention is not limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those with average knowledge in the art.
[0060] Experimental Example
[0061] [Experimental Example 1] Preparation of AAV-SIRT3 gene construct
[0062] As follows, an adeno-associated virus (AAV)-SIRT3 (NCBI gene ID of SIRT3: 23410) gene construct was prepared.
[0063] After introducing the human SIRT3 gene sequence into an AAV vector containing a chicken β-actin promoter, AAV1-GFP-T2A-hSIRT3 (AAV-SIRT3) was constructed by adding a GFP (green fluorescent protein) tag to confirm expression induction. The viral construct (viral packaging) containing the SIRT3 gene was commissioned to Vector BioLabs (Malvern, PA), and the gene titer was 1 × 10⁶. 12 It was viral genomes / mL. A viral gene construct prepared by subcloning GFP into the same plasmid was used as a negative control (gene titer: 1 × 10⁶ 12 It was used as viral genomes / mL.
[0064]
[0065] [Experimental Example 2] Administration of AAV-SIRT3 gene construct into mouse substantia nigra
[0066] Mice were anesthetized by intraperitoneal injection of a mixture of ketamine (115 mg / kg; Yuhan, Seoul, Republic of Korea) and xylazine (23 mg / kg; Bayer Korea Ltd, Seoul, Republic of Korea). Eight-week-old normal mice (C57BL / 6) were placed in a stereotaxic frame, and an AAV gene construct (AAV-GFP or AAV-SIRT3) was injected into bilateral substantia nigra regions (AP: -0.35 cm, ML: ± 0.11 mm, DV: -0.37 cm, relative to bregma) using a 10 µl Hamilton syringe (30S gauge needle). The AAV gene construct was injected at a rate of 0.1 µl / min for 20 minutes, with 2 µl of viral vector solution per substantia nigra region; the syringe was held in the same position for an additional 5 minutes immediately after injection to reduce backflow along the injection route.
[0067]
[0068] [Experimental Example 3] Analysis of mouse motor function
[0069] As described below, behavioral analyses (Rota-rod test, grip strength test) were performed to evaluate whether AAV-SIRT3 administration improved age-related decline in motor function.
[0070] For the rota-rod test, training was conducted for 3 days prior to the injection of the AAV gene construct, and mice were acclimatized to a rota-rod device (Scitech Inc., Seoul, Republic of Korea) containing a 3 cm diameter rotating rod at a speed of 10 rpm for 10 minutes. After the injection of the gene construct, the test was performed at 8-week intervals until 20 months of age at speeds ranging from 4 to 40 rpm for 5 minutes, and the time until falling off the rod was recorded. Each test was repeated three times at 60-minute intervals, and the average value was calculated.
[0071] The grip strength test measured the muscle strength of the forelimbs using an FGP-2 digital force gauge (NIDEC-SHIMPO Corporation, Kyoto, Japan). After inducing the mouse to grasp the grid, the maximum force at the point where it slowly pulled back and released the grid was measured in Newtons (N). Each test was repeated three times, and the average value was used as the result. Measurements were performed at 8-week intervals from 8 weeks of age to 20 months of age.
[0072]
[0073] [Experimental Example 4] Mouse Lean Body Mass Analysis
[0074] Mouse body composition was analyzed using the InAlyzer system (Medikors Inc., Seongnam, Republic of Korea), based on Dual-energy X-ray absorptiometry (DXA). Mice were anesthetized by inhalation with 2% isoflurane (Hana Pharm, Kyung-gi, Republic of Korea) for 4 minutes, and then positioned prone on the InAlyzer scanning bed with their limbs outward and their tails aligned straight behind their bodies. Each mouse was scanned a total of three times in 75-second optimal mode; high-energy scans were performed under conditions of 80 kV / 1.0 mA, and low-energy scans under conditions of 55 kV / 1.25 mA. Scan images were obtained without the mouse to remove the nose cone used for respiratory anesthesia, and these images were subsequently subtracted from the scan images to obtain refined data.
[0075] In the whole-body composition analysis, the tail region was excluded when setting the Region of Interest (ROI). The ROI for the forelimbs was defined as the range from the shoulder to the wrist, and for the hindlimbs as the range from the knee to the ankle. Lean body mass (LBM) was calculated according to the following formula; after calculating the values for each mouse's bilateral limbs, the average value was used as the final count for each individual.
[0076] LBM (%) = (lean mass / total mass) × 100,
[0077]
[0078] [Experimental Example 5] Western Blot Analysis
[0079] As described below, Western blot analysis was performed to analyze the expression levels of SIRT3 and related proteins in brain tissues, including the substantia nigra and striatum, and skeletal muscle tissues.
[0080] Brain tissue was transected using a brain matrix (Roboz Surgical Instrument Co., Gaithersburg, MD), and the substantia nigra and striatal regions were isolated. Skeletal muscle tissue was transected from the pectoral and limb skeletal muscles following body composition analysis. The isolated brain and skeletal muscle tissues were homogenized in lysis buffer containing a protease inhibitor cocktail (1:100, Millipore, Burlington, MA) and a phosphatase inhibitor cocktail (1:100, Cell Signaling Technology). The homogenized samples were centrifuged at 4°C and 14,000×g for 15 minutes, and the supernatant was transferred to a new tube for protein quantification. Protein concentration was measured using a BCA protein quantification kit (Bio-Rad Laboratories, Hercules, CA).
[0081] 50 μg of protein sample was electrophoresed on SDS-PAGE (Bio-Rad Laboratories) and then transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). The transferred membrane was blocked using TBST containing 5% BSA and then reacted with a primary antibody at 4°C for 48 hours. The major primary antibodies used are as follows: rabbit anti-TH (1:1000 dilution), rabbit anti-p-TH (1:1000 dilution), rabbit anti-SIRT3 (1:1000 dilution), mouse anti-β-actin (1:1000 dilution), rabbit anti-DRP1 (1:1000 dilution), rabbit anti-MFN2 (1:1000 dilution), mouse anti-ATP5A (1:1000 dilution), mouse anti-COXIV (1:1000 dilution), mouse anti-MTC02 (1:1000 dilution), rabbit anti-GFP (1:1000 dilution), mouse anti-synaptophysin (1:1000 dilution), mouse anti-p16 INK4a (1:500 dilution), mouse anti-NeuN(1:1000 dilution), mouse anti-SIRT1(1:1000 dilution), rabbit anti-SIRT2(1:1000 dilution), rabbit anti-SIRT4(1:1000 dilution), rabbit anti-SIRT5(1:1000 dilution), rabbit anti-SIRT6(1:1000 dilution), rabbit anti-SIRT7 (1:1000 dilution)
[0082] After the primary antibody reaction, HRP-conjugated secondary antibodies [anti-mouse IgG and anti-rabbit IgG (1:4000 dilution each)] were reacted at room temperature for 1 hour. Signal detection was performed using an enhanced chemiluminescence (ECL) reagent (GE Healthcare Life Science), and band intensity was measured using an ImageQuant LAS 500 imager (GE Healthcare Life Science). Quantitative analysis was performed using Image Gauge 4.0 (Fujifilm, Tokyo, Japan), and the expression level of each protein was calculated by normalizing to β-actin.
[0083]
[0084] [Experimental Example 6] Immunostaining Method
[0085] Mice were fixed via cardiac perfusion with 0.1M phosphate-buffered saline (PBS) containing 4% paraformaldehyde (PFA) and then transferred to a 30% sucrose solution to prevent damage during frozen sectioning. The fixed brains were frozen-sectioned into 30 µm thick coronal sections using an HM525 NX Cryostar microtome (Thermo Fisher Scientific).
[0086] For immunostaining, the sections were stained in a free-floating state before attaching to the glass slide. The substantia nigra and striatum sections were washed with 0.1M PBS and blocked in 0.1M PBS containing 0.5% BSA. Subsequently, they were incubated with primary antibodies at 4°C for 24 hours. After the primary antibody reaction, the sections washed with 0.1M PBS containing 0.5% BSA were incubated with an appropriate biotinylated secondary antibody, followed by incubation with the avidin-biotin complex (Vectastain ABC Kit) for 1 hour. Finally, color development was achieved by reacting with a solution containing 0.003% H₂O₂ and 0.5 mg / mL DAB in 0.1M phosphate buffer (PB). Stained sections were mounted on gelatin-coated slides (Paul Marienfeld, Germany), covered with coverslips, and observed using an Axio Imager optical microscope (Carl Zeiss, Jena, Germany).
[0087] For fluorescence immunostaining, sections were washed and blocked in the same manner, and then incubated with primary antibodies at 4°C for 24 hours. After the primary antibody reaction, the washed sections were reacted with Texas red-conjugated or FITC-conjugated secondary antibodies (anti-rabbit or anti-mouse IgG, 1:400 dilution) at room temperature for 1 hour. The stained sections were mounted on gelatin-coated slides, enclosed in Vectashield mounting medium (Vector Laboratories), and observed using an Axio Imager fluorescence microscope (Carl Zeiss, Gottingen, Germany).
[0088] The primary antibodies used for immunohistochemistry and fluorescence immunohistochemistry are as follows. Immunostaining: rabbit anti-SIRT3 (1:500 dilution), rabbit anti-TH (1:2000 dilution), rabbit anti-p-TH (1:1000 dilution), mouse anti-SIRT1 (1:200 dilution), and rabbit anti-SIRT7 (1:200 dilution).
[0089] 4',6-Diamidino-2-phenylindole (DAPI) dye was also used in fluorescent immunohistochemistry.
[0090]
[0091] [Experimental Example 7] Analysis of Dopamine and Metabolites (Homovanillic Acid, HVA)
[0092] As described below, High Performance Liquid Chromatography (HPLC) was performed to analyze the quantitative levels of dopamine and HVA in the substantia nigra and striatal regions.
[0093] After removing blood from mice by cardiac perfusion using 0.1M PBS, brain tissue was isolated to extract the substantia nigra and striatal regions. The brain tissue was placed in 400μL of a solution containing 0.1M perchloric acid and 0.1mM EDTA and homogenized, followed by centrifugation at 4°C and 9,000 rpm for 20 minutes. The resulting acid-soluble fraction was filtered using a 0.22μm membrane filter (Spin-X, Costar) and used for HPLC analysis.
[0094] For the analysis, an Agilent 1260 Infinity HPLC system (Agilent Technologies, Santa Clara, CA) and a Coulochem II electrochemical detector (ESA, Agilent Technologies) were used. 10 μL of the supernatant was injected into an autosampler (Waters 717 plus autosampler) maintained at 4°C and eluted through a μBondapak C18 column (4.6 × 100 mm, 5 μm; Waters Corporation, USA) using a mobile phase for catecholamine analysis (Chromosystems, Munich, Germany). Peaks corresponding to dopamine and HVA were identified by the electrochemical detector, and the data were integrated using ChemStation software (Agilent Technologies). All samples were normalized to protein concentration, and protein concentration was measured spectrophotometrically using a Bio-Rad protein assay kit (Bio-Rad Laboratories).
[0095]
[0096] [Experimental Example 8] RNA sequencing and gene expression analysis
[0097] Total RNA was extracted from substantia nigra tissue using TRIzol reagent (#15596026, Life Technologies, Carlsbad, CA) and subsequently purified according to the manufacturer's instructions using the miRNeasy Mini kit (217004, Qiagen Hilden, Germany). RNA quantification was performed using the Quant-IT RiboGreen assay (#R11490, Invitrogen, Waltham, MA), and RNA integrity was evaluated using TapeStation RNA ScreenTape (#5067-5576, Agilent Technologies). Only high-quality RNA with an RNA integrity number (RIN) of 7.0 or higher was selected for library construction.
[0098] RNA libraries were individually constructed using the Illumina TruSeq Stranded mRNA Sample Prep Kit (#RS-122-2101, Illumina, Inc., San Diego, CA) with 1 μg of total RNA per sample. mRNA containing a poly-A tail was purified, and RNA was collected using poly-T conjugated magnetic beads; the purified mRNA was fragmented under high temperature and divalent cation conditions. Subsequently, it was reverse transcribed into first-strand cDNA using SuperScript II reverse transcriptase (#18064014, Invitrogen) and random primers, followed by the synthesis of second-strand cDNA using DNA polymerase I, RNase H, and dUTP. The resulting double-stranded cDNA was amplified by PCR after undergoing end repair, A-tailing, and adapter ligation, and the final cDNA library was constructed.
[0099] The library was quantified using the KAPA Library Quantification Kit following the qPCR quantification protocol guide (#KK4854, Kapa Biosystems) and validated using TapeStation D1000 ScreenTape (#5067-5582, Agilent Technologies). The indexed library was sequenced in a paired-end (2×100 bp) manner using the Illumina NovaSeq platform from Macrogen Inc. (Seoul, Republic of Korea).
[0100] The generated sequencing data was aligned to the mouse (mm10) genome using the default options of HISAT2 v2.1.0, and the raw read count was calculated using HTSeq2 v0.12.4. Normalization and differentially expressed genes (DEGs) were calculated using DESeq2 v1.34.0, with the criteria set to fold change ≥ 2 and false discovery rate (FDR) < 0.05.
[0101] For Gene Ontology (GO) analysis, a list of genes related to GO: biological process (BP) and GO: cellular component (CC) was obtained from the Ensembl genome database, and the enrichment of GO terms was analyzed using hypergeometric distribution.
[0102]
[0103] Examples
[0104] Example 1. Comparison of SIRT3 expression in dopamine neurons of young mice (3 months old) and aged mice (20 months old)
[0105] Substantia nigra tissues from normal mice (C57BL / 6) aged 3 months and 20 months were isolated, and fluorescence immunostaining was performed using antibodies against dopamine neuron markers Tyrosine Hydroxylase (TH) and Sirtuin 3 (SIRT3), as well as 4',6-Diamidino-2-phenylindole (DAPI) dye to confirm target protein expression (Figure 1, left diagram). SIRT3 protein expression was stained in the same region as TH, a dopamine neuron marker, and a decrease in SIRT3 protein expression in the substantia nigra of aged mice (20 months) was confirmed compared to young mice (3 months).
[0106] Western blot analysis of TH, p-TH (dopamine neuronal activation marker), and SIRT3 protein expression was performed on isolated substantia nigra tissues from normal mice aged 3 months and 20 months, and it was confirmed that the expression levels of TH, p-TH, and SIRT3 proteins were significantly reduced in aged mice compared to young mice (right diagram of Fig. 1).
[0107]
[0108] Example 2. Confirmation of GFP expression in dopamine neurons after AAV-SIRT3-GFP injection into the mouse midbrain substantia nigra.
[0109] Four weeks after injecting Adeno-associated virus (AAV)-GFP (AAV control) and AAV-SIRT3 gene constructs into the substantia nigra region of normal mice aged 2 months, substantia nigra tissue was isolated, and the expression of target proteins was confirmed by fluorescence immunostaining using antibodies against TH, a dopamine neuron marker; DAPI, a cell marker; Glial fibrillary acidic protein (GFAP), an astrocyte marker; ionized calcium-binding adapter molecule 1 (Iba1), a microglia marker; and Green fluorescent protein (GFP) tagged with SIRT3 (Fig. 2).
[0110] As a result, by confirming that the expression of SIRT3 protein in the diagram stains in the same region as TH, a dopamine neuron, while not staining in the same region as GFAP, an astrocyte marker, and Iba1, a microglia marker, it was confirmed that the expression of target proteins through the introduction of AAV-GFP and AAV-SIRT3 into the substantia nigra is specifically expressed in dopamine neurons in the substantia nigra region.
[0111]
[0112] Example 3. Confirmation of increased expression of mitochondrial respiratory chain, ATP synthesis, and dopamine signaling pathway genes after AAV-SIRT3 injection into the mouse midbrain substantia nigra
[0113] Four weeks after injecting AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, substantia nigra tissue was isolated and RNA sequencing analysis was performed. Total RNA was extracted from the substantia nigra tissue, mRNA was isolated based on the poly-A tail, and an RNA library was constructed using it. Based on the RNA-seq results, differentially expressed genes (DEGs) were identified, and Gene Ontology [GO: cellular component (CC) and GO: biological process (BP)] analysis was performed on them.
[0114] As a result, increased expression of genes related to the mitochondrial respiratory chain, ATP synthesis, and dopamine signaling pathways was confirmed following the introduction of AAV-SIRT3 compared to normal and AAV-GFP controls.
[0115]
[0116] Example 4. SIRT3 and p16 in aged mice with AAV-SIRT3 introduced into the substantia nigra of the mouse midbrain INK4a Confirmation of expression of, mitochondrial-associated protein expression
[0117] After injecting AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, substantia nigra tissues were isolated at 3 and 20 months of age, respectively, and SIRT3, GFP, Cyclin-dependent kinase inhibitor 2A (p16 INK4a Western blot analysis was performed using antibodies for Dynamin-related protein 1 (DRP1, mitochondrial fission marker), Mitofusin 2 (MFN2, mitochondrial fusion marker), ATP synthase F1 subunit alpha (ATP5A, ATP synthase marker), Cytochrome c oxidase subunit IV (COXIV, respiratory chain Complex IV marker), and Mitochondrially encoded cytochrome c oxidase II (MTC02, respiratory chain Complex IV marker) to identify cellular senescence markers, and mitochondria-associated proteins (Figure 4, left diagram). Protein expression levels obtained from Western blot were analyzed using Image Gauge 4.0. Young mice (3 months) SIRT3, p16 INK4a Then, the criterion for mitochondrial-associated protein expression was set to a value of 1, and the protein expression levels of the remaining groups were compared.
[0118] As a result, it was confirmed that SIRT3 expression in the substantia nigra decreased by more than 50% in aged mice (20 months) compared to young mice (3 months), and p16 INK4a It was confirmed that the expression of increased by more than three times. On the other hand, in aged mice introduced with AAV-SIRT3, SIRT3 expression increased and p16 INK4aIt was confirmed that the expression of [variable] was reduced (center diagram of Fig. 4). In addition, it was confirmed that the expression of mitochondrial-associated proteins DRP1, MFN2, ATP5A, COXIV, and MTC02 in the substantia nigra of aged mice was reduced compared to young mice, and it was confirmed that in aged mice into which AAV-SIRT3 was introduced, the expression of mitochondrial-associated proteins was preserved at the level of young mice (right diagram of Fig. 4).
[0119]
[0120] Example 5. Confirmation of dopamine neuron preservation and quantitative preservation of dopamine metabolites in aged mice with AAV-SIRT3 introduced into the substantia nigra of the mouse midbrain
[0121] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, substantia nigra tissues were isolated at 20 months of age and immunohistochemistry was performed using TH antibodies, which are dopamine neuron markers (Figure 5, left diagram).
[0122] As a result, it was confirmed that the number of dopamine neurons in the substantia nigra decreased in aged mice (20 months) compared to young mice (3 months), whereas the number of dopamine neurons in the substantia nigra was preserved in aged mice introduced with AAV-SIRT3.
[0123] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, brain tissues were isolated at 3 months and 20 months of age, respectively, and immunohistochemistry and High Performance Liquid Chromatography (HPLC) were performed (right diagram of Fig. 5).
[0124] As a result, it was confirmed that the number of dopamine neurons in the striatum of aged mice introduced with AAV-SIRT3 was preserved, and that the expression levels of dopamine (striatal DA) and its metabolite Homovanillic Acid (HVA) were preserved.
[0125]
[0126] Example 6. Reduction in Apoptosis and Necrosis Protein Expression in Aged Mice Introduced with AAV-SIRT3 in the Substantia nigra of the Mouse Midbrain
[0127] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, substantia nigra tissues were isolated at 20 months of age and utilized antibodies against cleaved caspase-3 (c-caspase-3, apoptosis active marker), caspase-3 (apoptosis enzyme marker), cleaved poly(ADP-ribose) polymerase-1 (c-PARP-1, apoptosis active marker), Poly(ADP-ribose) polymerase-1 (PARP-1, DNA damage repair enzyme marker), phosphorylated Mixed Lineage Kinase Domain-Like protein (p-MLKL, necrosis active marker), Mixed Lineage Kinase Domain-Like protein (MLKL, necrosis-related protein marker), phosphorylated Receptor Interacting Protein Kinase 3 (p-RIP3, necrosis pathway active marker), and Receptor Interacting Protein Kinase 3 (RIP3, necrosis enzyme marker). Western blot analysis was performed (left diagram of Fig. 6).
[0128] As a result, it was confirmed that the expression of apoptosis (c-caspase-3, c-PARP-1) and necrosis (p-MLKL, p-RIP3) associated proteins in the substantia nigra increased in aged mice (20 months) compared to young mice (3 months), and that the expression of apoptosis and necrosis associated proteins decreased in aged mice with AAV-SIRT3 introduced into the substantia nigra (right diagram of Fig. 6).
[0129]
[0130] Example 7. Confirmation of improvement in aging-associated motor function and preservation of lean body mass in aged mice introduced with AAV-SIRT3 in the substantia nigra of the mouse midbrain
[0131] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, motor function analyses (Rota-rod test, Grip strength test) were performed at 2-month intervals until 20 months of age (left diagram of Fig. 7). The Rota-rod test, a motor function analysis presented in Fig. 7, involved placing a mouse on a rod that accelerated and rotated at 4–40 rpm for 5 minutes and measuring the time until it fell off. The Grip strength test involved slowly pulling the mouse holding the grid until it released the grid, and measuring the maximum force at the moment of release in Newtons (N).
[0132] In the Rota-rod test analysis, compared to untreated 16-month-old mice, the group with AAV-SIRT3 introduced into the substantia nigra of the same age group remained on the accelerating rotating rod for a longer period (left diagram of Fig. 7). Similarly, when compared to 18-month and 20-month-old mice, the group with AAV-SIRT3 introduced into the substantia nigra remained on the accelerating rotating rod for a longer period. The GFP control group showed nearly the same time spent on the rotating rod compared to the untreated mouse group (left diagram of Fig. 7).
[0133] In the analysis of the grip strength test, differences in Newton values—the force at the point of grasping and releasing the grid—began to appear compared to the AAV-SIRT3 substantia nigra introduction group of the same age group with untreated 12-month-old mice (left diagram of Fig. 7). It was confirmed that the pulling force of the grid was preserved in the AAV-SIRT3 substantia nigra introduction group of the same age group compared to the untreated 12-month-old mice. From 12 months to 20 months of age, the pulling force of the grid was consistently preserved in the AAV-SIRT3 substantia nigra introduction group of the same age group compared to the untreated mice (left diagram of Fig. 7).
[0134] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, lean body mass (LBM, the sum of body components excluding body fat) was analyzed at 20 months of age using Dual-energy X-ray absorptiometry (DXA) (right diagram of Fig. 7). The Region of Interest (ROI) was defined as the part of the trunk excluding the tail to calculate the total lean body mass; the forelimb was defined as the range from the shoulder to the wrist, and the hindlimb as the range from the knee to the ankle. Lean body mass was calculated as the ratio of tissue mass within the ROI, and after calculating for each limb separately, the average value was used as the final figure for each individual. As a result, preservation of lean body mass at the level of young mice was confirmed in aged mice introduced with AAV-SIRT3.
[0135]
[0136] Example 8. p16 in the muscle region of aged mice with AAV-SIRT3 introduced into the substantia nigra of the mouse midbrain INK4a Confirmation of reduced expression and preservation of Synaptophysin protein expression
[0137] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, muscle tissue from 20-month-old mice was isolated and the cellular senescence marker p16 INK4a Western blot analysis was performed using the synapse marker Synaptophysin antibody (left diagram of Fig. 8). Muscle tissue was separated into pectorals, forelimbs, and hindlimbs for analysis, and aged mice compared to young mice p16 INK4a While the expression of increased and Synaptophysin expression decreased, in aged mice introduced with AAV-SIRT3, p16 INK4a It was confirmed that the expression of decreased and the expression of Synaptophysin was preserved (right diagram of Fig. 8).
[0138]
[0139] Example 9. Confirmation of gene expression and protein expression levels of the SIRT family (SIRT1–7) after AAV-SIRT3 injection into the substantia nigra of the mouse midbrain
[0140] After injecting AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, substantia nigra tissue from 3-month-old mice was isolated and analyzed by RNA sequencing (top diagram of Fig. 9).
[0141] As a result, it was confirmed that the gene expression of SIRT3 and SIRT7 increased in the AAV-SIRT3-introduced group compared to normal mice that received no treatment.
[0142] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, substantia nigra tissues were isolated at 3 and 20 months of age, respectively, and Western blot analysis was performed using SIRT3 family (SIRT1–7) antibodies (middle section of Fig. 9).
[0143] As a result, it was confirmed that protein expression of SIRT3 and SIRT7 increased in young and aged mice introduced with AAV-SIRT3, and that SIRT1 protein expression was preserved at the level of young mice in aged mice introduced with AAV-SIRT3. Additionally, it was confirmed that the introduction of AAV-SIRT3 did not affect the protein expression of SIRT2, SIRT4, SIRT5, and SIRT6.
[0144] After injecting AAV-GFP and AAV-SIRT3 into the substantia nigra region of normal mice aged 2 months, substantia nigra tissues were isolated at 3 months and 20 months of age, respectively, and immunohistochemistry was performed using SIRT1 and SIRT3 antibodies (bottom diagram of Fig. 9).
[0145] As a result, preservation of SIRT1 protein and increased SIRT7 protein expression in the substantia nigra were confirmed in aged mice introduced with AAV-SIRT3.
[0146]
[0147] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. That is, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
1. A pharmaceutical composition for the prevention or treatment of sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient.
2. A pharmaceutical composition according to claim 1, characterized in that the composition induces anti-aging within dopamine neurons of the substantia nigra.
3. A pharmaceutical composition according to claim 1, characterized in that the anti-aging factor regulates the anti-aging of the substantia nigra-striatal dopamine nervous system of the midbrain.
4. A pharmaceutical composition according to claim 1, characterized in that the composition is a gene therapy agent.
5. A pharmaceutical composition according to claim 4, characterized in that the gene therapy agent is introduced into the substantia nigra of the midbrain.
6. A pharmaceutical composition according to claim 1, characterized in that the anti-aging factor is one or more SIRT families selected from the group consisting of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.
7. The pharmaceutical composition according to claim 1, characterized by the effect of improving age-related exercise function and preserving lean body mass.
8. A pharmaceutical composition according to claim 1, characterized in that the sarcopenia is obese sarcopenia or age-related sarcopenia.
9. A health functional food composition for preventing or improving sarcopenia comprising an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient.
10. A feed composition for preventing or improving sarcopenia containing an anti-aging factor within the substantia nigra-striatal dopamine nervous system as an active ingredient.
11. A method for treating sarcopenia comprising the step of administering a composition containing an anti-aging factor as an active ingredient to an individual.
12. A treatment method according to claim 11, characterized in that the composition is a gene therapy agent.
13. A treatment method according to claim 12, characterized in that the gene therapy agent is introduced into the substantia nigra of the midbrain.
